7.80
price up icon0.00%   0.00
after-market 시간 외 거래: 7.88 0.08 +1.03%
loading
전일 마감가:
$7.80
열려 있는:
$7.71
하루 거래량:
55,358
Relative Volume:
0.95
시가총액:
$53.04M
수익:
$100.44M
순이익/손실:
$-133.16M
주가수익비율:
-0.3028
EPS:
-25.76
순현금흐름:
$-94.85M
1주 성능:
+9.24%
1개월 성능:
+3.86%
6개월 성능:
-35.93%
1년 성능:
-45.09%
1일 변동 폭
Value
$7.4419
$7.88
1주일 범위
Value
$7.20
$8.0999
52주 변동 폭
Value
$5.005
$18.70

아타라 Stock (ATRA) Company Profile

Name
명칭
Atara Biotherapeutics Inc
Name
전화
805-623-4211
Name
주소
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Name
직원
89
Name
트위터
@Atarabio
Name
다음 수익 날짜
2024-11-18
Name
최신 SEC 제출 서류
Name
ATRA's Discussions on Twitter

ATRA을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
ATRA
Atara Biotherapeutics Inc
7.80 42.56M 100.44M -133.16M -94.85M -25.76
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

아타라 Stock (ATRA) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2023-11-09 다운그레이드 Evercore ISI Outperform → In-line
2023-11-09 다운그레이드 H.C. Wainwright Buy → Neutral
2023-11-09 다운그레이드 Mizuho Buy → Neutral
2022-07-20 다운그레이드 Citigroup Neutral → Sell
2022-07-13 다운그레이드 JP Morgan Overweight → Neutral
2022-07-13 다운그레이드 Stifel Buy → Hold
2022-05-10 다운그레이드 Citigroup Buy → Neutral
2021-05-13 업그레이드 JP Morgan Neutral → Overweight
2020-12-09 다운그레이드 Citigroup Buy → Neutral
2020-12-08 재확인 H.C. Wainwright Buy
2020-11-10 재확인 H.C. Wainwright Buy
2020-06-30 개시 Evercore ISI Outperform
2020-06-15 개시 H.C. Wainwright Buy
2020-04-23 업그레이드 Citigroup Neutral → Buy
2019-11-08 다운그레이드 JP Morgan Overweight → Neutral
2019-09-27 다운그레이드 Goldman Neutral → Sell
2019-09-16 다운그레이드 Jefferies Buy → Hold
2019-06-04 업그레이드 Citigroup Sell → Neutral
2019-05-30 개시 ROTH Capital Buy
2019-05-23 개시 Stifel Buy
2019-01-23 개시 Mizuho Buy
2018-04-10 개시 JP Morgan Overweight
2018-03-16 개시 Guggenheim Neutral
2018-03-05 재확인 Jefferies Buy
2018-02-28 다운그레이드 JMP Securities Mkt Outperform → Mkt Perform
2018-02-15 다운그레이드 Citigroup Neutral → Sell
2018-01-03 업그레이드 Citigroup Sell → Neutral
2017-10-06 재개 Goldman Neutral
모두보기

아타라 주식(ATRA)의 최신 뉴스

pulisher
May 29, 2025

Redmile Group, LLC's Strategic Acquisition in Atara Biotherapeutics Inc - GuruFocus

May 29, 2025
pulisher
May 28, 2025

Here's Why You Should Consider Buying Atara Biotherapeutics Stock - Barchart.com

May 28, 2025
pulisher
May 27, 2025

(ATRA) Trading Advice - news.stocktradersdaily.com

May 27, 2025
pulisher
May 22, 2025

Layoff Tracker: Boundless Laying Off 33% of Staff - BioSpace

May 22, 2025
pulisher
May 22, 2025

Atara Biotherapeutics (NASDAQ:ATRA) & Turnstone Biologics (NASDAQ:TSBX) Financial Analysis - Defense World

May 22, 2025
pulisher
May 20, 2025

Top Executives at Atara Biotherapeutics Make Significant Stock Sales! - TipRanks

May 20, 2025
pulisher
May 20, 2025

Atara Biotherapeutics Executives Sell Shares for Tax Obligations - TradingView

May 20, 2025
pulisher
May 20, 2025

Citadel Advisors LLC Has $3.56 Million Position in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - Defense World

May 20, 2025
pulisher
May 19, 2025

FDA Delivers Blow to ImmunityBio - Los Angeles Business Journal

May 19, 2025
pulisher
May 19, 2025

Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors - BioSpace

May 19, 2025
pulisher
May 18, 2025

Atara Biotherapeutics (ATRA) Expands Board Following $16 Million Offering | ATRA Stock News - GuruFocus

May 18, 2025
pulisher
May 17, 2025

Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors | ATRA Stock News - GuruFocus

May 17, 2025
pulisher
May 17, 2025

Atara Biotherapeutics Reports Strong Q1 2025 Results - TipRanks

May 17, 2025
pulisher
May 16, 2025

(ATRA) Investment Analysis and Advice - news.stocktradersdaily.com

May 16, 2025
pulisher
May 16, 2025

Atara Biotherapeutics Announces $16M Stock Offering - TipRanks

May 16, 2025
pulisher
May 16, 2025

Atara Biotherapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance

May 16, 2025
pulisher
May 16, 2025

Atara Biotherapeutics: Q1 Earnings Snapshot - CT Insider

May 16, 2025
pulisher
May 16, 2025

Atara Biotherapeutics sets stock and warrant offering prices By Investing.com - Investing.com India

May 16, 2025
pulisher
May 15, 2025

Atara Biotherapeutics prices $16M public offering - MSN

May 15, 2025
pulisher
May 15, 2025

Atara Biotherapeutics (ATRA) Announces $16M Share Offering - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress | ATRA Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Atara Biotherapeutics sets stock and warrant offering prices - Investing.com

May 15, 2025
pulisher
May 15, 2025

Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress - BioSpace

May 15, 2025
pulisher
May 15, 2025

Atara Biotherapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 15, 2025
pulisher
May 15, 2025

Atara Biotherapeutics Announces Pricing of $16 Million Offering - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Atara Biotherapeutics, Inc. SEC 10-Q Report - TradingView

May 15, 2025
pulisher
May 15, 2025

Atara Biotherapeutics Announces Pricing of $16 Million Offering | ATRA Stock News - GuruFocus

May 15, 2025
pulisher
May 12, 2025

Atara Biotherapeutics Announces Major Workforce Reduction - TipRanks

May 12, 2025
pulisher
May 12, 2025

Atara Biotherapeutics To Reduce Workforce By 30% - marketscreener.com

May 12, 2025
pulisher
May 12, 2025

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World

May 12, 2025
pulisher
May 10, 2025

Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

May 10, 2025
pulisher
May 07, 2025

FDA lifts clinical hold on Atara’s Ebvallo - The Pharma Letter

May 07, 2025
pulisher
May 06, 2025

FDA Lifts Hold on Atara’s EBVALLO Program - TipRanks

May 06, 2025
pulisher
May 06, 2025

Atara Does An About Face As FDA Lifts Ebvallo Hold - insights.citeline.com

May 06, 2025
pulisher
May 06, 2025

(ATRA) Investment Analysis - news.stocktradersdaily.com

May 06, 2025
pulisher
May 06, 2025

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Shares Fly 30% But Investors Aren't Buying For Growth - simplywall.st

May 06, 2025
pulisher
May 06, 2025

Atara Biotherapeutics Says FDA Lifts Clinical Hold on Ebvallo Investigational New Drug Applications - marketscreener.com

May 06, 2025
pulisher
May 06, 2025

FDA Lifts Hold on Atara Biotherapeutics' Ebvallo Program | ATRA Stock News - GuruFocus

May 06, 2025
pulisher
May 05, 2025

Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel) | ATRA Stock News - GuruFocus

May 05, 2025
pulisher
May 05, 2025

Atara Biotherapeutics Says FDA Lifts Clinical Hold Enabling Resumption Of Clinical Trials - marketscreener.com

May 05, 2025
pulisher
May 05, 2025

Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel) - Business Wire

May 05, 2025
pulisher
May 05, 2025

Atara Biotherapeutics, Inc. Provides Regulatory Updates on EBVALLO?? (Tabelecleucel) - marketscreener.com

May 05, 2025
pulisher
May 02, 2025

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Shares Acquired by Geode Capital Management LLC - Defense World

May 02, 2025
pulisher
Apr 29, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 29, 2025

아타라 (ATRA) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
자본화:     |  볼륨(24시간):